200 related articles for article (PubMed ID: 30341987)
1. Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety.
Dada R; Usman B
Eur J Haematol; 2019 Feb; 102(2):150-156. PubMed ID: 30341987
[TBL] [Abstract][Full Text] [Related]
2. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
Manson G; Mear JB; Herbaux C; Schiano JM; Casasnovas O; Stamatoullas A; Deau B; Schmitt A; Garnier G; Regny C; Bouabdallah K; Moles-Moreau MP; Ghesquieres H; Tempescul A; Dulery R; Nicolas-Virelizier E; Delmer A; Borel C; Chauchet A; Damotte D; Dercle L; Brice P; Houot R;
Eur J Cancer; 2019 Jul; 115():47-56. PubMed ID: 31082693
[TBL] [Abstract][Full Text] [Related]
4. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
Steinerová K; Jindra P; Lysák D; Karas M
Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
[TBL] [Abstract][Full Text] [Related]
5. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J;
Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
8. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.
Khaddour K; Musiek A; Cornelius LA; Dehdashti F; Westervelt P; Fields R; Ansstas G
J Immunother Cancer; 2019 Dec; 7(1):338. PubMed ID: 31801591
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
14. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
Casadei B; Broccoli A; Stefoni V; Pellegrini C; Marangon M; Morigi A; Nanni L; Lolli G; Carella M; Argnani L; Cavo M; Zinzani PL
Haematologica; 2019 Nov; 104(11):e521-e522. PubMed ID: 30890595
[No Abstract] [Full Text] [Related]
16. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.
Schoch LK; Cooke KR; Wagner-Johnston ND; Gojo I; Swinnen LJ; Imus P; Fuchs EJ; Levis M; Ambinder RF; Jones RJ; Gladstone DE
Blood Adv; 2018 Sep; 2(17):2226-2229. PubMed ID: 30190282
[TBL] [Abstract][Full Text] [Related]
19. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
[TBL] [Abstract][Full Text] [Related]
20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
